Portal de Periódicos da CAPES

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

2021; Springer Nature; Volume: 35; Issue: 9 Linguagem: Inglês

10.1038/s41375-021-01270-w

1476-5551

Lindsey E. Roeker, David A. Knorr, Meghan C. Thompson, Mariely Nivar, Sonia Lebowitz, Nicole V. Peters, Isaac Deonarine, Saddia Momotaj, Saumya Sharan, Vanessa Chanlatte, Bianca Hampton, Liana Butala, Lindsay Amato, Angela Richford, Jessica Lunkenheimer, Kristen Battiato, Carissa Laudati, Anthony R. Mato,

Phagocytosis and Immune Regulation

While randomized controlled trials demonstrated 94-95% efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines [1, 2], efficacy in immunocompromised patients has not been established.We aimed to understand serologic response to mRNA vaccination in patients with chronic lymphocytic leukemia (CLL), a population of interest given the immunocompromised state associated with this malignancy and disease-directed therapies, as well as incomplete immune responses following other vaccinations [3][4][5][6][7][8][9][10].